![PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan | Hoda Atef - Academia.edu PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan | Hoda Atef - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/67747136/mini_magick20210625-7756-f5myfh.png?1624660415)
PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan | Hoda Atef - Academia.edu
![Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet](https://www.thelancet.com/cms/attachment/92c78bdc-c776-4547-8c9f-25d568de4172/gr1_lrg.gif)
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet
![PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan](https://i1.rgstatic.net/publication/261521666_Effect_of_Spironolactone_on_Diabetic_Nephropathy_Compared_to_the_Combination_of_Spironolactone_and_Losartan/links/550e0f6f0cf27526109ca5b8/largepreview.png)
PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan
![Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double‐blind, randomized controlled VaSera trial - Faconti - Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double‐blind, randomized controlled VaSera trial - Faconti -](https://bpspubs.onlinelibrary.wiley.com/cms/asset/5a86e4bd-4d70-4c72-a144-add33d830bf1/bcp13783-toc-0001-m.png)
Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double‐blind, randomized controlled VaSera trial - Faconti -
![Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial - The Lancet Diabetes & Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial - The Lancet Diabetes &](https://www.thelancet.com/cms/attachment/e8276df5-2f9e-4e37-bd07-e313ed200bf4/gr1.gif)
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial - The Lancet Diabetes &
![Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population | BMC Research Notes | Full Text Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population | BMC Research Notes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13104-016-1987-5/MediaObjects/13104_2016_1987_Fig1_HTML.gif)
Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population | BMC Research Notes | Full Text
![The Effects of Adding Spironolactone to ACEI or ARB on Proteinuria in Type 2 Diabetes | Semantic Scholar The Effects of Adding Spironolactone to ACEI or ARB on Proteinuria in Type 2 Diabetes | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/da50a225b14f6db26c5f890750fd4e30743f015c/5-Figure3-1.png)
The Effects of Adding Spironolactone to ACEI or ARB on Proteinuria in Type 2 Diabetes | Semantic Scholar
![JCM | Free Full-Text | Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease JCM | Free Full-Text | Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease](https://pub.mdpi-res.com/jcm/jcm-07-00459/article_deploy/html/images/jcm-07-00459-g001.png?1570727050)
JCM | Free Full-Text | Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease
![Frontiers | Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling Frontiers | Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling](https://www.frontiersin.org/files/Articles/149990/fphys-06-00269-r2/image_m/fphys-06-00269-g007.jpg)
Frontiers | Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling
![Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension | Journal of Human Hypertension Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension | Journal of Human Hypertension](https://media.springernature.com/w300/springer-static/image/art%3A10.1038%2Fjhh.2014.27/MediaObjects/41371_2015_Article_BFjhh201427_Figa_HTML.jpg)
Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension | Journal of Human Hypertension
![Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes - ScienceDirect Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1931524420300736-gr5.jpg)
Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes - ScienceDirect
![Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy - ScienceDirect Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002962918300521-gr1.jpg)
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy - ScienceDirect
![PDF) Effect of Spironolactone and Amiloride on Thiazolidinedione-Induced Fluid Retention in South Indian Patients with Type 2 Diabetes PDF) Effect of Spironolactone and Amiloride on Thiazolidinedione-Induced Fluid Retention in South Indian Patients with Type 2 Diabetes](https://i1.rgstatic.net/publication/233774752_Effect_of_Spironolactone_and_Amiloride_on_Thiazolidinedione-Induced_Fluid_Retention_in_South_Indian_Patients_with_Type_2_Diabetes/links/54bf829b0cf28ce68e6b5af7/largepreview.png)